A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

There is a significant unmet need for additional treatment options for high-grade NMIBC, especially in those ineligible for BCG.

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Gene Holdings Inc. rises on 62% CR rate in Phase 2 NMIBC trial. Click to learn about ENGN and its gene delivery tech, market ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...